AGRX logo

Agile Therapeutics, Inc. Stock Price

OTCPK:AGRX Community·US$10.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

AGRX Share Price Performance

US$0
0.00 (0.00%)
US$0
0.00 (0.00%)
Price US$0

AGRX Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Moderate and slightly overvalued.

5 Risks
1 Reward

Agile Therapeutics, Inc. Key Details

US$21.6m

Revenue

US$7.8m

Cost of Revenue

US$13.7m

Gross Profit

US$29.6m

Other Expenses

-US$15.9m

Earnings

Last Reported Earnings
Jun 30, 2024
Next Reporting Earnings
n/a
-2.30
63.63%
-73.52%
0%
View Full Analysis

About AGRX

Founded
1997
Employees
19
CEO
Alfred Altomari
WebsiteView website
www.agiletherapeutics.com

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Recent AGRX News & Updates

Recent updates

No updates